report banner

News in English

PostPress Release

HoloMonitor provide vital information to development of improved child cancer treatment

Learn more …
PostNews: Press Release

PHI achieves market acceptance goals

Prior to the company’s IPO in early 2014, three market acceptance goals were set out to be achieved by the end of 2015: 50 units in operation at customers and key opinion leaders, collaboration agreements with 8 key opinion leaders and the company’s main product HoloMonitor® M4 shall be manufactured in series production.
Learn more …
PostPress Release

PHI invited to speak at world leading scientific event

Learn more …
PostNews: Press Release

Big Pharma embraces HoloMonitor technology from PHI

Upon completion of an extensive evaluation in early September one of the top pharmaceutical companies in the world has decided to acquire two HoloMonitor® instruments. The ordered configuration is an automated version of the HoloMonitor platform.
Learn more …
PostNews: Press Release

HoloMonitor technology help researchers fight ovarian cance

Ovarian cancer is one of the deadliest forms of cancer. Researchers at the Center of Excellence for Holographic Imaging at Northeastern University in Boston have used HoloMonitor technology to study how the immune system can be stimulated to fight this deadly cancer form. The research results have been published in Journal of Clinical & Cellular Immunology.
Learn more …
PostPress Release

Phase Holographic Imaging receives first order from United Kingdom after exhibition

Learn more …
1232425262730